Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504861 | 1.00 | OPRM1 (0.53) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30230017 | 0.95 | OPRM1 (0.58) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30229795 | 0.91 | REN (0.54) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30229695 | 0.90 | REN (0.56) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30229850 | 0.90 | REN (0.56) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL16212659 | 0.89 | C5AR1 (0.54) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30504860 | 0.88 | C5AR1 (0.52) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30339782 | 0.87 | CTSL (0.55) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL14921065 | 0.86 | C5AR1 (0.49) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30229960 | 0.86 | CTSL (0.51) | OPRM1OPRK1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | OPRM1 4384/4885OPRK1 4090/4885CTSL 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.